Results 91 to 100 of about 44,548 (260)

Phenotypic correlations of CALR mutation variant allele frequency in patients with myelofibrosis

Blood Cancer Journal, 2023
Paola Guglielmelli, Chiara Maccari, Benedetta Sordi, Manjola Balliu, Alessandro Atanasio, Carmela Mannarelli, Giulio Capecchi, Ilaria Sestini, Giacomo Coltro, Giuseppe Gaetano Loscocco, Giada Rotunno, Eva Angori, Filippo C. Borri, Ayalew Tefferi, Alessandro M. Vannucchi   +14 more
doaj   +1 more source

Transcription factor mutations in myelodysplastic/myeloproliferative neoplasms

Haematologica, 2010
Background Aberrant activation of tyrosine kinases, caused by either mutation or gene fusion, is of major importance for the development of many hematologic malignancies, particularly myeloproliferative neoplasms.
Thomas Ernst, Andrew Chase, Katerina Zoi, Katherine Waghorn, Claire Hidalgo-Curtis, Joannah Score, Amy Jones, Francis Grand, Andreas Reiter, Andreas Hochhaus, Nicholas C.P. Cross   +10 more
doaj   +1 more source

The role of neutrophils in the pathophysiology of inflammatory bowel diseases

Periodontology 2000, EarlyView.
Abstract Objectives Inflammatory bowel disease (IBD) encompasses a spectrum of chronic disorders of the gastrointestinal tract, with a potential bidirectional relationship with periodontitis. Neutrophils are key regulators of immune‐inflammatory responses and play a major role in both diseases.
Joao Paulo Steffens, Ekin Yay‐Kus, Rafael Scaf de Molon, Viorelia Stoica, Peter Rimmer, Josefine Hirschfeld, Asif Jilani Iqbal, Tariq Iqbal, Iain Chapple   +8 more
wiley   +1 more source

Modernising diagnosis and treatment of Chronic Myeloid Leukaemia for improved patient outcomes in a resource-limited setting: Experiences from Ghana’s premier teaching hospital

Journal of Interventional Epidemiology and Public Health
Introduction: Until 2013, diagnosis of Chronic Myeloid Leukaemia (CML) at Korle-Bu Teaching Hospital (KBTH) in Ghana was based on white blood cell morphology ascertained from peripheral blood and bone marrow aspirate.
Amma Anima Benneh-Akwasi Kuma, Michael Mauro   +1 more
doaj   +1 more source

Molecular analyses of 15,542 patients with suspected BCR-ABL1-negative myeloproliferative disorders allow to develop a stepwise diagnostic workflow

Haematologica, 2012
We investigated 15,542 patients with suspected BCR-ABL1- negative myeloproliferative or myelodysplastic/myeloproliferative neoplasm (including 359 chronic myelomonocytic leukemia) by a molecular marker set.
Susanne Schnittger, Ulrike Bacher, Christiane Eder, Frank Dicker, Tamara Alpermann, Vera Grossmann, Alexander Kohlmann, Wolfgang Kern, Claudia Haferlach, Torsten Haferlach   +9 more
doaj   +1 more source

Targeting phosphatidylinositol-3-kinase pathway for the treatment of Philadelphia-negative myeloproliferative neoplasms [PDF]

, 2015
Myeloproliferative neoplasms (MPN) are a diverse group of chronic hematological disorders that involve unregulated clonal proliferation of white blood cells.
Kapur, Reuben, Pandey, Ruchi
core   +1 more source

Outcomes of dengue infection in adults with underlying haematological diseases in Brazil during 2024 and 2025

British Journal of Haematology, EarlyView.
K. Tozatto‐Maio, V. Weihermann, C. W. Erthal, M. W. Araújo, C. R. Gomes, K. Caciola, L. Otuyama, J. Gasparini, H. R. Higashino, S. F. Costa, A. N. Duarte‐Neto, F. S. Seguro, P. R. Villaça, E. D. R. P. Velloso, S. F. M. Gualandro, Y. Nukui, V. Rocha   +16 more
wiley   +1 more source

DP133 | CIP2A IS IMPLICATED IN RUXOLITINIB RESISTANCE IN MYELOFIBROSIS

Haematologica
Although ruxolitinib (Ruxo) is the standard of care for patients (pts) with myelofibrosis (MF), therapeutic resistance develops in approximately 50% within 3-5 years, posing a clinical challenge.
M. Balliu, M. Vannucchi, M.C. Siciliano, M. Lomi, C. Basile, P. Guglielmelli, A.M. Vannucchi   +6 more
doaj  

Estimating the prevalence of hematological malignancies and precursor conditions using data from Haematological Malignancy Research Network (HMRN) [PDF]

, 2016
Objective: Well-established cancer registries that routinely link to death registrations can estimate prevalence directly by counting patients alive at a particular point in time (observed prevalence).
Crouch, Simon, Li, Jinlei, Oliver, Steven Edward, Roman, Eve, Smith, Alexandra Gwen   +4 more
core   +1 more source

C019 | INIBITION OF PI3KΔ BY ROGINOLISIB (IOA-244) AS A POTENTIAL THERAPEUTIC STRATEGY FOR MYELOFIBROSIS

Haematologica
Due to its clonal stem cell origins and the resulting dysregulation of the JAK/STAT pathway, myelofibrosis (MF) treatment has undergone a paradigm shift with the development of JAK-inhibitors.
M. Balliu, G. Di Conza, M. Lahn, P. Guglielmelli, A.M. Vannucchi   +4 more
doaj